CS
CGON icon

Candriam SCA’s CG Oncology CGON Stock Holding History

Candriam SCA’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.3M Sell
469,170
-72,866
-13% -$4.76M 0.15% 144
2026
Q1 		$36.7M Sell
542,036
-255,579
-32% -$14.5M 0.19% 120
2025
Q4 		$33.1M Sell
797,615
-240,277
-23% -$9.94M 0.17% 134
2025
Q3 		$41.8M Buy
1,037,892
+274,312
+36% +$7.97M 0.22% 103
2025
Q2 		$19.9M Buy
+763,580
New +$18.4M 0.11% 167

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's CGON Position: Q2 2026 in Review

Candriam SCA reduced its CG Oncology (CGON) stake by 13% in Q2 2026, selling an estimated $4.76M and leaving 469,170 shares worth $33.3M. The position accounts for 0.15% of the portfolio, ranked #144.

Candriam SCA first reported a position in CGON in Q2 2025 and has held it in 5 quarters since. The position peaked at $41.8M in Q3 2025. 228 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Candriam SCA held 469,170 shares of CG Oncology worth $33.3M as of Q2 2026.
  • Candriam SCA sold 72,866 CG Oncology shares in Q2 2026, an estimated $4.76M.
  • CG Oncology made up 0.15% of Candriam SCA's portfolio in Q2 2026, its #144 holding.
  • Candriam SCA first reported a position in CG Oncology in Q2 2025 and has held it in 5 quarters since.
  • Candriam SCA's CG Oncology position peaked at $41.8M in Q3 2025.
  • 228 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.